ScoreRheumatology, allergy and dermatology
PEN-FAST (penicillin allergy)
Estimates the probability that a reported penicillin allergy is confirmed on testing.
Updated 30 October 2026
When to use it
Adults labelled as penicillin-allergic, to choose between a direct oral challenge and allergy referral.
Warning
With a history of severe cutaneous adverse reaction (SJS/TEN, DRESS, AGEP) a drug challenge must not be performed, whatever the score.
What it needs
- Reaction 5 years ago or less (or unknown)
- Anaphylaxis or angioedema
- Severe cutaneous adverse reaction (SJS/TEN, DRESS, AGEP)
- The reaction required treatment (or unknown)
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 0 | Very low risk (< 1 % positive tests) |
| 1–2 | Low risk (≈ 5 %): candidate for a direct oral challenge |
| 3 | Moderate risk (≈ 20 %): refer for allergy testing |
| ≥ 4 | High risk (≈ 50 %): refer for allergy testing |
Practical tip
A score < 3 identifies patients with very few positive tests (≈ 4 %); in the PALACE trial a direct oral challenge in this group was as safe as skin-test-guided care.
2 more practical tips in the app.
Reference
- Trubiano JA, Vogrin S, Chua KYL, et al. Development and validation of a penicillin allergy clinical decision rule. JAMA Intern Med. 2020;180(5):745-752.
- Copaescu AM, Vogrin S, James F, et al. Efficacy of a clinical decision rule to enable direct oral challenge in patients with low-risk penicillin allergy: the PALACE randomized clinical trial. JAMA Intern Med. 2023;183(9):944-952.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
